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Abstract: Apoptosis inducing factor (AIF) has been proposed to act as a putative reactive oxygen species  scavenger in 
mitochondria. When apoptotic cell death is triggered, AIF translocates to the nucleus, where it leads to nuclear chromatin 
condensation and large-scale DNA fragmentation which result in caspase-independent neuronal death. We performed this 
study to investigate the possibility that, in addition to caspase-dependent neuronal death, AIF induced neuronal death could 
be a cause of neuronal death in Alzheimer’s disease (AD). We have found that AIF immunoreactivity was increased in the 
hippocampal pyramidal neurons in the Alzheimer brains compared to those of healthy, age-matched control brains. Nuclear 
AIF immunoreactivity was detected in the apoptotic pyramidal CA1 neurons at the early stage of AD and CA2 at the advanced 
stage. Nuclear AIF positive neurons were also observed in the amygdala and cholinergic neurons of the basal forebrain (BFCN) 
from the early stages of AD. Th   e results of this study imply that AIF-induced apoptosis may contribute to neuronal death within 
the hippocampus, amygdala, and BFCN in early of AD. 
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interrupt microtubular function and lead to neuronal dege-
neration and cell death [2]. Clinically, AD is characterized by 
progressive impairment of cognition and emotional distur-
bances that are strongly correlated with synaptic degeneration 
and death of neurons in limbic structures such as the hippo-
campus and the amygdala and associated regions of the cere-
bral cortex [3]. In particular, the hippocampus plays a key 
role in memory function and is severely affected from the 
early stage of AD. There are reports of neuronal loss in the 
CA1 region of the hippocampus in early onset AD brains. 
The neuronal loss increases significantly with the duration 
or severity of the disease [4]. Although the exact cause and 
mechanism of neuronal loss in AD is not yet clear, extensive 
recent literature supports oxidative stress, mitochondrial 
dysfunction, and calcium dyshomeostasis as early contributors 
in AD pathology, occurring prior to the development of 
detectable plaques and tangles [5-9]. Longstanding oxidative 
Introduction
Th   e central hypotheses on the pathogenesis of Alzheimer’s 
disease (AD) are the Amyloid and Tau hypotheses. The 
amy  loid hypothesis is based on an imbalance between 
the production and clearance of β-amyloid (Aβ) in brain 
[1], leading to plaque formation, consequential neuronal 
degeneration, and dementia. The tau hypothesis states that 
hyperphosphorylated tau is easy to aggregate and eventually 
forms neurofibrillary tangles. The intracellular tangle may AIF-induced neuronal death of AD
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stress has been suggested as one of the important candidates 
for the development of AD pathology [6]. Little is known, 
however, about the molecular mechanisms of oxidative stress 
by which it mediates neuronal cell death in AD. 
Apoptosis is a cell death program that is central to cellular 
and tissue homeostasis, and is involved in many physiological 
and pathological processes [10]. Apoptosis is characterized 
morphologically by a series of events that include cytoplasmic 
shrinkage, chromatin condensation, nuclear and cellular frag-
mentation, and the formation of apoptotic bodies. Although 
caspases are the main players involved in apoptosis, there are 
other molecules involved in the progression of the apoptotic 
cascade that are relevant to AD. 
Apoptosis inducing factor (AIF) has been proposed to act 
as a putative reactive oxygen species scavenger [11]. Upon 
patho  logical permeabilization of the outer mitochondrial 
mem  brane, mature AIF is further processed to a ~57 kDa 
form by activated calpains and/or cathepsins [12]. Th  e  soluble 
proapoptotic form of AIF is now called truncated AIF (tAIF). 
Th   is isoform is translocated to the nucleus via its C-terminal 
domain nuclear localization sequence, which leads to large-
scale DNA fragmentation [12, 13], a hallmark of caspase-
independent apoptosis. Although research on AIF-induced 
neuronal death has been focused on acute insults, evidence is 
mounting recently that AIF-induced neuronal death could be 
related to chronic neurodegenerative diseases. 
Th   e possibility that AIF-induced cell death may be invol-
ved in neuronal death in chronic neurodegenerative disease 
has been raised by some researchers in the past few years. 
One group examined AIF protein levels in cortical areas 
of the human brain at various ages and in AD [14]. They 
reported that there was no signifi  cant diff  erence in AIF pro-
tein levels from the cortex and hippocampus of AD patients 
versus age-matched control brains. Th   e same group recently 
reported cellular and subcellular distributions of AIF in the 
hippocampus, entorhinal, and medial temporal cortices in 
postmortem samples of late AD patients [15]. However, a 
focused analysis of the precise impact of AIF on cell death 
has not yet been studied. Further investigation is therefore 
required to determine the role, if AIF in AD pathology. 
In order to investigate the possibility of early involvement 
of AIF in AD pathology, we examined the expression of AIF 
in the various limbic regions of the age-matched control 
brains and AD brains, which were classified according to 
progression of pathology as early AD (Braak stage I and II) 
and advanced AD brains (Braak stage III-VI). 
Materials and Methods
Reagents and antibodies
AIF (sc-9416) antibody was purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Fluorescein 
avidin D (A-2001), avidin-biotin blocking solution (SP-2001), 
Vectashield (H-1000) and biotinylated anti-goat IgG (BA-
5000) were supplied by Vector Laboratories (Burlingame, 
CA, USA). Hoechst 33342 (bis-Benzimide H33342 trihy-
drochloride, 14533) and DAB (3,3'-diaminobenzidine 
tetrahydrochloride, D-5905) were supplied by Sigma Aldrich 
(St. Louis, MO, USA). 
Subjects
Fourteen age-matched control brains with no clinical or 
neuropathologic evidence of AD were obtained within 24 
postmortem hours from the cadavers of the Department 
of Anatomy and Neuroscience in the School of Medicine 
at Eulji University. Consent was given for brain donation 
by next-of-kin in all cases, and a postmortem examination 
was conducted by the Anatomy laboratory according to 
stan  dardized protocols. All experimental procedures were 
performed in accordance with ‘The Guidelines of the IRB 
(Ethics Committee) at Eulji University.’ A total of fourteen 
brain hemispheres obtained by autopsy were fixed in 10% 
neutral buffered formalin. The fixed hemispheres were cut 
on the coronal plane, and blocks were selected from 10 to 
15 brain areas for pathologic diagnosis and comprehensive 
evaluation of the neurodegenerative process. They were 
prepared according to routine histological procedures for 
paraffin section. The twenty-six Alzheimer brains were 
generously gifted from Dr. Roger A. Brumback and were 
diagnosed by him. All brains were processed according to 
same protocols. Th   e regions were cut on the coronal plane at 
8   m thicknesses for immunohistochemical study, or 20 μm 
for confocal microscopic immunofluorescence study, then 
mounted on poly-L-lysine-coated slides. The sections were 
deparaffinized and hydrated according to routine graded 
xylene-alcohol methods. Hematoxylin and eosin (H&E) and 
Luxol fast blue/cresyl violet (LFB-CV) stains were done for 
general histopathology. Modifi  ed silver stain by Campbell et 
al. [16] for detecting the senile plaque and Gallyas stain [17] 
for detecting neurofibrillary tangles (NFT) were employed. 
The modified Campbell’s silver staining method is a 
combination of Campbell and Gallyas staining. Th  e  technique 
was carried out as previously described [18]. Th   e detailed data Anat Cell Biol 2012;45:26-37 Ji-Hye Lee, et al 28
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for each brain is summarized in Table 1.
Immunohistochemistry
In order to retrieve antigenecity, dewaxed sections were 
boiled within 0.1 mol/L citrate-buff  ered saline (pH 6.0) for 10 
minutes. Aft  er cooling down for 30 minutes, the sections were 
rinsed in phosphate buffered saline (PBS). The endogenous 
peroxidase was quenched by 1% hydrogen peroxide in 10% 
methanol for 30 minutes. Aft  er two changes of PBS-T (0.1% 
Triton X-100 in 0.1 mol/L PBS, pH 7.6) washing for 5 minutes 
each, the sections were blocked for 1 hour in blocking 
solu  tion (5% rabbit serum+1% bovine serum albumin in 
PBS-T) and incubated in primary antibody (anti-AIF, 1 : 
200) at 4
oC overnight. Aft  er PBS-T rinses, the sections were 
incubated in a biotinylated secondary antibody for 1 hour 
at room temperature (RT). Aft  er PBS rinsing and an avidin-
biotin-peroxidase complex (Vectastain Elite ABC kit, Vector 
Laboratories) treatment for 1 hour at RT, the sections were 
developed for 5 minutes in a 0.05% DAB solution. As a 
negative control for nonspecific staining, the sections were 
Table 1. Th   e brains studied
Case Groups Age (y) Sex Brain weight (g) Braak stage (Aβ) Braak stage (NFT)
1 Age-matched control 50 F 1,175 0 0
2 Age-matched control 50 M 1,278 0 0
3 Age-matched control 54 F 1,200 0 0
4 Age-matched control 56 M 1,275 0 0
5 Age-matched control 56 M 1,292 0 0
6 Age-matched control 56 M 1,405 0 0
7 Age-matched control 57 F 1,179 0 0
8 Age-matched control 59 M 1,415 0 0
9 Age-matched control 61 M 1,391 0 0
10 Age-matched control 61 F 1,212 0 0
11 Age-matched control 67 M 1,210 0 0
12 Age-matched control 71 M 1,300 0 0
13 Age-matched control 73 M 1,323 0 0
14 Age-matched control 79 F 1,280 0 0
15 Early AD 51 F 1,179 B 0
16 Early AD 55 M 1,380 B 0
17 Early AD 56 M 1,285 A 0
18 Early AD 60 F 1,200 B 0
19 Early AD 64 F 1,030 B 0
20 Early AD 67 M 1,148 A I
21 Early AD 68 M 1,280 B I
22 Early AD 69 M 1,440 B II
23 Early AD 72 M 1,390 B II
24 Early AD 76 M 1,350 A I
25 Early AD 76 M 1,340 B II
26 Early AD 79 F 1,200 B II
27 Early AD 79 F 1,220 B II
28 Early AD 83 F 1,264 B I
29 Early AD 87 F 1,220 A II
30 Advanced AD 72 F 820 C VI
31 Advanced AD 72 F 850 C VI
32 Advanced AD 73 M 1,250 C VI
33 Advanced AD 75 F 1,020 C V
34 Advanced AD 76 M 1,350 C IV
35 Advanced AD 81 M 1,120 C V
36 Advanced AD 81 M 920 C VI
37 Advanced AD 82 F 550 C VI
38 Advanced AD 83 M 1,200 C V
39 Advanced AD 84 M 1,050 C VI
40 Advanced AD 89 F 1,050 C V
Aβ, β-amyloid; NFT, neurofi  brillary tangles; F, female; M; male; AD, Alzhimer’s disease.AIF-induced neuronal death of AD
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incubated with initial incubation media minus the primary 
antibody, and otherwise processed as described. Images were 
captured with an Axiocam digital camera (Carl Zeiss Co., 
Jena, Germany) attached to an Olympus AX70 microscope 
(Olympus, Tokyo, Japan). 
Confocal microscope immunofl  uorescence
To detect whether the AIF expressed in the apoptotic 
pyramidal neurons was translocated to the nucleus, we per-
formed confocal immunofluorescence study on the same 
section. Pre-staining processes were the same as described. 
Th   e sections were incubated in primary antibody (anti-AIF, 
1 : 50) overnight at 4
oC. They were washed and incubated 
with the appropriate secondary biotinylated antibody. After 
PBS rinsing, the sections were incubated with FITC avidin 
D. Th   en, nuclear stain was done with 10 μM Hoechst 33342 
for 30 minutes. To reduce background, the sections were 
incubated in 10% Sudan black B solution for 5 minutes, and 
then rinsed with distilled, deionized water and mounted with 
Vectashield. The AIF immunoreactivity was visualized with 
FITC fluorescence (green), and nuclear stain was detected 
with Hoechst 33342 fluorescence (blue) under UV on the 
same section. The images were captured with an LSM 510 
meta system (Zeiss LSM 510 laser scanning microscope, Carl 
Zeiss Co.).
Imaging, labeling index determination, and statistical 
analysis
Except for the confocal microscopic images, all images 
were captured using an Olympus AX70 microscope outfi  tted 
with an Axiocam digital camera. The final magnifications 
were 100×, 200×, and 400×, and the capture frame size was 0.3 
mm
2. Th   e selected anatomical regions included hippocampus, 
amygdala and cholinergic neurons of the basal forebrain 
(BFCN). Within each region, two images were captured at 
evenly spaced intervals to represent the entire area of interest. 
Th   e numbers of AIF-positive cells (nuclear AIF staining) were 
expressed as the mean number of cells per mm
2 of the cross 
sectional area in the age-matched control, the early AD, and 
the advanced AD brains. To prevent a potential bias toward 
lower counts of neurons positive for AIF in severe AD cases 
resulted from neuronal loss, all counts were standardized 
with respect to the total number of neurons counted. Stati-
stical analysis was conducted with Graph Pad Prism (Graph-
Pad software, San Diego, CA, USA). For multiple group 
comparisons, statistical differences were calculated by one-
way ANOVA followed by Dunnett’s test. Values of P<0.05 
were considered signifi  cant.
Results
Immunohistochemical diagnosis in the AD hippo-
campus
All brains (age-matched control and AD) were assigned 
according to the neuropathological staging by Braak and 
Braak [19]. Th   e three groups are referred to as normal (age-
matched control), and mildly (early AD) or severely aff  ected 
(advanced AD), referring to the extent of NFT and senile 
plaque in the hippocampus. Postmortem examination confi  r-
med the diagnosis of AD given by the presence of abundant 
amyloid deposits and neurofibrillary tangles, and H&E and 
LFB-CV staining also demonstrated marked cell loss (Fig. 1A-
C). 
Expression of AIF in the hippocampus of AD brains
The nuclear translocation of AIF can induce caspase-
independent neuronal death [13]. We thus determined the 
proportion of AIF positive pyramidal neurons (displaying a 
nuclear AIF) versus total pyramidal neurons. No immuno-
reactive product was detected on the negative reaction con-
trol section (Fig. 2A, top panel). In age-matched control, 
AIF immunoreactivity was detected in the cytoplasm 
of the pyramidal neuron of the CA1-CA3 sectors (Fig. 
2A). We perceived that AIF immunoreactivity in the AD 
brain was distinguishable from the age-matched control 
as AD progresses. In the early and advanced AD brains, 
AIF immunoreactivity was detected in the nucleus of the 
hippocampal pyramidal neuron in all CA sectors (Fig. 
2A). We found that AIF immunoreactivity was increased 
in the CA1, 2, 3 sectors in AD brains as compared to age-
matched control. (Fig. 2B-D). In particular, nuclear AIF 
immunoreactivity was notably higher in the apoptotic 
pyramidal neuron of the CA1 in the early AD brains and 
of the CA2 in the advanced AD brains (Fig. 2B, C). These 
results suggest that AIF-induced apoptosis is involved in AD 
progression 
Nuclear translocation of AIF within apoptotic pyra-
midal neurons in the hippocampus of AD brains
No immunoreaction product was visible on negative 
con  trol sections (data not shown). Fig. 3A and B show that Anat Cell Biol 2012;45:26-37 Ji-Hye Lee, et al 30
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in age-matched control brains, AIF was localized in cyto-
plasm but not in the nucleus. In early AD, AIF immuno-
reac  tivity was increased in the cytoplasm of most of the 
pyra  midal neurons. In advanced AD brains, nuclear AIF 
immunoreactivity was mainly observed in cells showing nu-
clear condensation and pyknosis. To confirm the nuclear 
translocation of AIF, we performed immunofluorescence 
for AIF and a nuclear marker, Hoechst 33342. In early AD, 
AIF immunofluorescence in cytoplasm was more intense 
compared to the age-matched control (Fig. 3B). Nuclear AIF 
immunofluorescence was mainly observed in the apoptotic 
cells with condensed nucleuses (Fig. 3B, boxed area of the 
lower panel). It is supposed that the nuclear translocation 
of AIF could be associated with nuclear condensation and 
cellular shrinkage of the hippocampal pyramidal neuron in 
the AD brain.
Nuclear translocation of AIF in the corticomedial 
nucleus of amygdala of AD brains
AD is strongly correlated with cell loss and death of neu-
Fig. 1. Pathological changes of pyramidal 
neurons and plaques in Alzhimer’s 
disease (AD) brains. (A) Light micro-
graphs of the CA1 region of the hip-
pocampus. Hema  toxylin and eosin 
(H&E), Luxol fast blue/cresyl violet 
(LFB-CV) and modifi  ed Camp  bell’s silver 
stain were sequentially applied to the 
semi-serial sections. Scale bar=100 μm. 
(B) Quan  ti  tative analysis of data in (A) 
shows neu  ronal loss of the hippocampal 
pyramidal neurons. (C) Quantitative 
analysis of data in (A) shows the number 
of plaques in CA1. n=14 for age-
matched control, n=15 for early AD 
and n=11 for advanced AD. *P<0.05, 
†P<0.01.  AIF-induced neuronal death of AD
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rons in the limbic structures, such as the hippocampus and 
the amygdala, and the associated regions of cerebral cortex [3]. 
Campbell’s staining confi  rmed amyloid deposits and NFT (for 
AD diagnosis). H&E and LFB-CV staining also demonstrated 
marked cell loss (Fig. 4A). 
To further determine whether AIF immunoreactivity was 
changed in the corticomedial nucleus of amygdala of AD 
brain, we investigated that expression of AIF in those regions. 
The number of neurons in the corticomedial nucleus of 
theamygdala was decreased with AD progression (Fig. 4B). 
In early AD, nuclear AIF immunoreactivity was signifi  cantly 
increased in comparison to age-matched control (Fig. 4C). In 
advanced AD, nuclear AIF immunoreactivity was increased 
as well, but had no statistical signifi  cance. 
Nuclear translocation of AIF in the BFCN of AD 
brains
The BFCN undergo selective loss in neurodegenerative 
disorders of the elderly, specifi  cally, AD [20]. So we investi-
gated the expression of AIF in the BFCN of AD brains. Th  e 
number of basal forebrain cholinergic neurons was reduced 
signifi  cantly with AD progression (Fig. 5B). In age-matched 
control, AIF immunoreactivity was detected in the cytoplasm 
of large neurons which were assumed to be cholinergic (Fig. 
5A). In early AD, nuclear AIF immunoreactivity signifi  cantly 
increased compared to age-matched control (Fig. 5C). In 
advanced AD, nuclear AIF immunoreactivity was increased 
as well, but had no statistical signifi  cance.
Fig. 2. (A) Apoptosis inducing factor (AIF) immunoreactivity in the CA1, CA2, and CA3 regions of the age-matched control, early Alzhimer’s 
disease (AD), and advanced AD brains. Top panels are negative control of CA1. Scale bar=50 μm. (B-D) Quantitative analysis of incidence (% of 
nuclear AIF positive neurons/total neurons per section) of nuclear AIF-positive neurons in the CA1 (B), CA2 (C), and CA3 regions (D). n=14 
for age-matched control, n=15 for early AD, and n=11 for advanced AD. 
†P<0.01. Anat Cell Biol 2012;45:26-37 Ji-Hye Lee, et al 32
www.acbjournal.org http://dx.doi.org/10.5115/acb.2012.45.1.26
Discussion
AD is the most common cause of dementia. Among the 
many other pathological hallmarks, neuronal loss is con-
sidered as one of the main causative events of dementia in 
this catastrophic disease. The neuronal death in AD may 
result directly and/or indirectly from the triggering insults 
caused by Aβ toxicity, glutamate excitotoxicity, long-lasting 
oxidative stress, DNA damage, and elevation of intracellular 
calcium levels [3]. Th   us, the mode of cell death in AD remains 
a matter of controversy [21], and it is possible that both 
apoptotic and non-apoptotic cell death coexist in the brains of 
aff  ected patients. 
Apoptosis, a type programmed cell death (PCD), is not 
always harmful. It is widely involved in normal regulatory 
life events and to some extent participates in pathologic 
events as well. Since the duration of the apoptotic process is 
relatively short, only a few cells that are undergoing apop-
tosis can be detected at a single moment in the course of 
a chronic neurodegenerative disease [22]. Previously, it 
was generally considered that apoptotic neuronal death in 
chro  nic neurodegenerative disease, e.g., AD, Parkinson’s 
disease, etc., is associated with classical caspase mediated cell 
death [23-26]. However, in part, it was suggested that the 
Fig. 3. Nuclear translocation of apoptosis inducing factor (AIF) in the apoptotic pyramidal neurons. (A) In age-matched control, AIF 
immunoreactivity is detected in the cytoplasm of pyramidal neurons. In early Alzhimer’s disease (AD), the intensity of AIF immunoreactivity 
(boxed area) increases in cytoplasm and the nucleus as well, but nuclear morphology is not conspicuously altered. In advanced AD, the apoptotic 
pyramidal neurons showing nuclear AIF immunoreactivity (boxed area) are shrunken, and their nuclei are serrated, which implies nuclear damage. 
(B) Confocal immunofl  uorescence micrographs showing the nuclear translocation of AIF in the hippocampal pyramidal neurons of early AD. In 
age-matched control, AIF (FITC) is detected exclusively in the cytoplasm of the neurons (upper panel; boxed area). In early AD, the overlay of AIF 
and Hoechst 33342 (lower panel; boxed area) indicates that AIF has translocated into the nucleus. Th   e nuclear translocation of AIF is associated 
with nuclear pyknosis and cellular shrinkage. Nuclei are stained with Hoechst 33342. Scale bars=100 μm (A, B), 5 μm (inset, enlarged areas of 
boxed area in A), 10 μm (inset, enlarged areas of boxed area in B).AIF-induced neuronal death of AD
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caspase-independent pathway might also participate in the 
pathogenesis of the disease [27, 28]. According to Yang et al. 
[29], occasional neurons in brain sections of older PS/APP 
mice displayed abnormal morphological changes such as cell 
shrinkage, condensed nucleus and cytoplasmic organelles, 
and evidence of plasmalemmal blebbing. These features 
and the appearance of corkscrew-like dendrites in some 
neurons correspond to so-called “dark neurons.” On sections 
processed with anti-activated caspase-3 antibodies, few, if any, 
silver-gold particles were detected in dark neurons, indicating 
that caspase 3 is not activated in the dark neurons. Th  us,  the 
existence of at least two modes of neurodegeneration in the 
Fig. 4. Apoptosis inducing factor (AIF) immunohistochemistry in the corticomedial nucleus of the amygdala of Alzhimer’s disease (AD) brains. 
(A) Hematoxylin and eosin (H&E), Luxol fast blue/cresyl violet (LFB-CV) and modifi  ed Campbell’s silver stain and AIF immunohistochemistry 
of the corticomedial nucleus of amygdala. Scale bars=100 μm. (B) Quantitative analysis of the corticomedial neuron loss in (A). (C) Quantitative 
analysis of the incidence of the AIF-positive neurons in the corticomedial nucleus. n=14 for age-matched control, n=15 for early AD, and n=11 
for advanced AD. *P<0.05, 
†P<0.01. Anat Cell Biol 2012;45:26-37 Ji-Hye Lee, et al 34
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same mouse model underscores the complexity of cell death 
patterns in chronic neurodegenerative disease. Cross talk 
is extensive between different cell death pathways, which 
include multiple types of caspase-dependent and caspase-
independent programmed cell death. AIF appears to play 
an important role in acute neural tissue damage induced 
by trauma, hypoglycemia, transient ischemia, and chronic 
neurodegenerative diseases. Bahi et al. [30] demonstrated that 
experimental ischemia in embryonic cardiomyocytes triggers 
caspase activation, but the mode of cell death switches into 
caspase-independent PCD in diff  erentiated cardiomyocytes. 
Although it is the result of in vitro procedures, it indicates that 
Fig. 5. Apoptosis inducing factor (AIF) immunohistochemistry in the cholinergic neurons of the basal forebrain (BFCN) of Alzhimer’s 
disease (AD) brains. (A) Hematoxylin and eosin (H&E), Luxol fast blue/cresyl violet (LFB-CV) and modifi  ed Campbell’s silver stain and AIF 
immunohistochemistry of the BFCN. Scale bars=100 μm. (B) Quantitative analysis of the neuronal loss in BFCN in (A). (C) Quantitative 
analysis of the incidence of the AIF positive neurons in the BFCN. n=14 for age-matched control, n=15 for early AD, and n=11 for advanced AD. 
*P<0.05, 
†P<0.01. AIF-induced neuronal death of AD
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the cell death mechanisms are diff  erent depending on the cell’s 
status. Unlike in vivo, in vitro study indicates that the forms 
of cell death are the same and that the translocation of AIF is 
not caused by nuclear shrinkage [31], because AIF is clearly 
seen in the nucleus at early points in time when the nucleus is 
clearly distinguishable from cytoplasmic structures. For many 
years, there has been some debate about whether there is 
apoptotic cell death in AD and whether it is in anyway related 
to cognitive impairment and dementia. While the study of 
apoptosis and apoptotic mechanisms is fairly easy to perform 
in cell culture systems and animal models, it is much more 
difficult in human organs including the brain. A few years 
ago, it was demonstrated that Aβ-induced neuronal apoptosis 
lead to AIF translocation from mitochondria to the nucleus 
in embryonic rat cortical cultures [32]. Interestingly, both 
mitochondrial and nuclear eff  ects of AIF have been observed 
in neuronal death associated with rodent aging and acute 
traumatic injuries [11, 33]. What was shown is consistent with 
a possible involvement of AIF in neuronal cell death on AD 
pathology. Interestingly, a study on AIF protein levels in the 
cortical areas of human brains at various ages and in AD was 
reported [14]. Recently, a study by the same group provided 
the fi  rst demonstrations of increased nuclear translocation of 
AIF and its colocalization with NFT in the AD brain in mid-
to late stages, but not in early stages [15]. Studies on defi  ning 
the plausible mechanism and role of AIF on cell death in 
AD human brains have not been widely performed thus far. 
In this article, the focus has been centered on the possibility 
of early involvement of AIF in neurodegeneration and cell 
death in AD. This study proposes that the dysfunction of 
neurons precedes the obvious pathological abnormalities 
and that the intraneuronal molecular changes caused by 
this stress-induced injury are subtle. The present study was 
noteworthy in documenting AIF protein expression in the 
hippocampal pyramidal neurons in human AD brains. Our 
study confi  rmed caspase 3 immunoreactivity in AD (data not 
shown). Our in vivo results suggest that the AIF-mediated 
caspase-independent apoptotic pathway associated with dark 
neurons may be involved in the hippocampal pyramidal 
neuron death from early stages of AD.
The basal forebrain contains a population of large choli-
nergic neurons and is subdivided into four groups, Ch1-
Ch4 [34, 35]. Ch4, which is very prevalent in human brains, 
most closely corresponds to the nucleus basalis of Meynert 
which is embedded in the substantia innominata, and at least 
90% of the neurons in the nucleus basalis are cholinergic. 
It is well known in AD that the cholinergic neurons in the 
nucleus basalis of Meynert undergo a profound and selective 
degeneration from the early stages of the disease [36, 37]. 
The amygdala is a gray mass situated in the dorsomedial 
portion of the temporal lobe. It has been known that the 
amyg  dala is involved from in early AD. The amygdala nu-
clear complex is divided into two main nuclear masses: a 
corticomedial nuclear group and a basolateral nuclear group. 
The cholinergic innervation of the amygdala in human is 
severely aff  ected in case of AD [38]. It is still debated whether 
it is the reduction in cholinergic innervations or other mecha-
nisms that directly influence on the neuronal death in the 
amygdala. Early studies reported that the neurons in the cor-
ticomedial nuclear group are extensively degenerated from 
the early stage, but the neurons in the basolateral nuclear 
group are not [39, 40]. In summary, in order to identify the 
involvement of AIF-mediated caspase-independent cell death 
in the pathology of AD, we investigated the AIF protein 
expression in the hippocampus, amygdala, and BFCN in 
accordance with AD progression. The major findings are 
that 1) AIF immunoreactivity is increased in the nucleus of 
hippocampal pyramidal neurons in the AD brain, and the 
expression of this molecule is altered in accordance with 
the progression of AD. 2) From the early stage of AD, AIF is 
translocated into the nucleus of apoptotic pyramidal neurons. 
3) AIF immunoreactivity was increased in the neurons of 
corticomedial nucleus of the amygdala and BFCN in early AD 
and the neurons showing nuclear translocation of AIF were 
also increased in early AD in comparison to the age-matched 
control in those areas. Unfortunately, we do not have proper 
specimens for biochemical study which would be helpful 
in identifying the precise molecular mechanism involved 
in AIF induced cell death in AD, and thus our study is 
inevitably limited only to morphological study. Although our 
information is not enough to solve the exact molecular events 
involved, this study gives the first morphological evidence 
that from early stages of AD, caspase-independent neuronal 
death is also involved in the pathogenesis of AD. Our results 
may provide a novel concept for developing new therapeutic 
strategies against chronic neurodegenerative diseases. To 
identify, however, the precise molecular mechanism involved 
in AIF-mediated neuronal death in AD, further investigations 
will be required.Anat Cell Biol 2012;45:26-37 Ji-Hye Lee, et al 36
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